BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Lopez CE, Legge KL. Influenza A Virus Vaccination: Immunity, Protection, and Recent Advances Toward A Universal Vaccine. Vaccines (Basel) 2020;8:E434. [PMID: 32756443 DOI: 10.3390/vaccines8030434] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 6.0] [Reference Citation Analysis]
Number Citing Articles
1 Liang Y, Liu X, Hu J, Huang S, Ma X, Liu X, Wang R, Hu X. The crude extract from the flowers of Trollius chinensis Bunge exerts anti-influenza virus effects through modulation of the TLR3 signaling pathway. Journal of Ethnopharmacology 2023;300:115743. [DOI: 10.1016/j.jep.2022.115743] [Reference Citation Analysis]
2 Jangra S, Laghlali G, Choi A, Rathnasinghe R, Chen Y, Yildiz S, Coughlan L, García-sastre A, De Geest BG, Schotsaert M. RIG-I and TLR-7/8 agonists as combination adjuvant shapes unique antibody and cellular vaccine responses to seasonal influenza vaccine. Front Immunol 2022;13. [DOI: 10.3389/fimmu.2022.974016] [Reference Citation Analysis]
3 Liu X, Zhao T, Wang L, Li M, Sun C, Shu Y. Strategies targeting hemagglutinin cocktail as a potential universal influenza vaccine. Front Microbiol 2022;13:1014122. [DOI: 10.3389/fmicb.2022.1014122] [Reference Citation Analysis]
4 Fadilah NQ, Jittmittraphap A, Leaungwutiwong P, Pripdeevech P, Dhanushka D, Mahidol C, Ruchirawat S, Kittakoop P. Virucidal Activity of Essential Oils From Citrus x aurantium L. Against Influenza A Virus H 1 N 1:Limonene as a Potential Household Disinfectant Against Virus. Natural Product Communications 2022;17:1934578X2110727. [DOI: 10.1177/1934578x211072713] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
5 Rees AR. Influenza virus: an evolving chameleon. A New History of Vaccines for Infectious Diseases 2022. [DOI: 10.1016/b978-0-12-812754-4.00007-8] [Reference Citation Analysis]
6 Mayburd A. Cross-testing of direct-action antivirals, universal vaccines, or search for host-level antivirals: what will sooner lead to a generic capability to combat the emerging viral pandemics? Expert Rev Anti Infect Ther 2021;:1-5. [PMID: 34719314 DOI: 10.1080/14787210.2022.2000859] [Reference Citation Analysis]
7 Moore KA, Ostrowsky JT, Kraigsley AM, Mehr AJ, Bresee JS, Friede MH, Gellin BG, Golding JP, Hart PJ, Moen A, Weller CL, Osterholm MT; Influenza Vaccines R&D Roadmap Taskforce. A Research and Development (R&D) roadmap for influenza vaccines: Looking toward the future. Vaccine 2021;39:6573-84. [PMID: 34602302 DOI: 10.1016/j.vaccine.2021.08.010] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 11.0] [Reference Citation Analysis]
8 Cáceres CJ, Cardenas-Garcia S, Jain A, Gay LC, Carnaccini S, Seibert B, Ferreri LM, Geiger G, Jasinskas A, Nakajima R, Rajao DS, Isakova-Sivak I, Rudenko L, Vincent AL, Davies DH, Perez DR. Development of a Novel Live Attenuated Influenza A Virus Vaccine Encoding the IgA-Inducing Protein. Vaccines (Basel) 2021;9:703. [PMID: 34198994 DOI: 10.3390/vaccines9070703] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
9 Díez JM, Romero C, Cruz M, Vandeberg P, Merritt WK, Pradenas E, Trinité B, Blanco J, Clotet B, Willis T, Gajardo R. Anti-SARS-CoV-2 hyperimmune immunoglobulin provides potent and robust neutralization capacity and antibody-dependent cellular cytotoxicity and phagocytosis induction through N and S proteins.. [DOI: 10.1101/2021.06.11.447942] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
10 Boccalini S, Pariani E, Calabrò GE, DE Waure C, Panatto D, Amicizia D, Lai PL, Rizzo C, Amodio E, Vitale F, Casuccio A, DI Pietro ML, Galli C, Bubba L, Pellegrinelli L, Villani L, D'Ambrosio F, Caminiti M, Lorenzini E, Fioretti P, Micale RT, Frumento D, Cantova E, Parente F, Trento G, Sottile S, Pugliese A, Biamonte MA, Giorgetti D, Menicacci M, D'Anna A, Ammoscato C, LA Gatta E, Bechini A, Bonanni P. [Health Technology Assessment (HTA) of the introduction of influenza vaccination for Italian children with Fluenz Tetra®]. J Prev Med Hyg 2021;62:E1-E118. [PMID: 34909481 DOI: 10.15167/2421-4248/jpmh2021.62.2s1] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
11 Penkert RR, Patel N, Webby RJ, Ross TM, Hurwitz JL. Month of Influenza Virus Vaccination Influences Antibody Responses in Children and Adults. Vaccines (Basel) 2021;9:68. [PMID: 33498232 DOI: 10.3390/vaccines9020068] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
12 Husain M. Host factors involved in influenza virus infection. Emerg Top Life Sci 2020;4:389-98. [PMID: 33210707 DOI: 10.1042/ETLS20200232] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
13 Marchi S, Manini I, Kistner O, Piu P, Remarque EJ, Manenti A, Biuso F, Carli T, Lazzeri G, Montomoli E, Trombetta CM. Serologically-Based Evaluation of Cross-Protection Antibody Responses among Different A(H1N1) Influenza Strains. Vaccines (Basel) 2020;8:E656. [PMID: 33167390 DOI: 10.3390/vaccines8040656] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]